# Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)

> **NCT00765518** · PHASE2 · COMPLETED · sponsor: **Vericel Corporation** · enrollment: 40 (actual)

## Conditions studied

- Dilated Cardiomyopathy

## Interventions

- **BIOLOGICAL:** Ixmyelocel-T
- **OTHER:** Standard of Care

## Key facts

- **NCT ID:** NCT00765518
- **Lead sponsor:** Vericel Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2012-09-05
- **Final completion:** 2012-09-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2021-05-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00765518

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00765518, "Use of Ixmyelocel-T (Formerly Cardiac Repair Cell [CRC] Treatment) in Patients With Heart Failure Due to Dilated Cardiomyopathy (IMPACT-DCM)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00765518. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*